Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 9 results
Author
[
Title
]
Type
Year
Filters:
Author
is
Chen-Kiang, Selina
[Clear All Filters]
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
T
Mark TM
,
Bowman IA
,
Rossi AC
,
Shah M
,
Rodriguez M
,
Quinn R
,
Pearse RN
,
Zafar F
,
Pekle K
,
Jayabalan D
et al.
. 2014.
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
.
Leuk Lymphoma. 55(12):2842-9.
P
Niesvizky R
,
Ely S
,
Mark T
,
Aggarwal S
,
Gabrilove JL
,
Wright JJ
,
Chen-Kiang S
,
Sparano JA
. 2011.
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
.
Cancer. 117(2):336-42.
Niesvizky R
,
Badros AZ
,
Costa LJ
,
Ely SA
,
Singhal SB
,
Stadtmauer EA
,
Haideri NA
,
Yacoub A
,
Hess G
,
Lentzsch S
et al.
. 2015.
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
.
Leuk Lymphoma. 56(12):3320-8.
L
Niesvizky R
,
Naib T
,
Christos PJ
,
Jayabalan D
,
Furst JR
,
Jalbrzikowski J
,
Zafar F
,
Mark T
,
Lent R
,
Pearse RN
et al.
. 2007.
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
.
Br J Haematol. 138(5):640-3.
G
Wei X
,
M Calvo-Vidal N
,
Chen S
,
Wu G
,
Revuelta MV
,
Sun J
,
Zhang J
,
Walsh MF
,
Nichols KE
,
Joseph V
et al.
. 2018.
Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.
.
Cancer Res. 78(10):2747-2759.
C
Gay F
,
S Rajkumar V
,
Coleman M
,
Kumar S
,
Mark T
,
Dispenzieri A
,
Pearse R
,
Gertz MA
,
Leonard J
,
Lacy MQ
et al.
. 2010.
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
.
Am J Hematol. 85(9):664-9.
Ely S
,
Forsberg P
,
Ouansafi I
,
Rossi A
,
Modin A
,
Pearse R
,
Pekle K
,
Perry A
,
Coleman M
,
Jayabalan D
et al.
. 2017.
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
.
Clin Lymphoma Myeloma Leuk. 17(12):825-833.
B
Niesvizky R
,
Jayabalan DS
,
Christos PJ
,
Furst JR
,
Naib T
,
Ely S
,
Jalbrzikowski J
,
Pearse RN
,
Zafar F
,
Pekle K
et al.
. 2008.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
.
Blood. 111(3):1101-9.
A
Mark T
,
Jayabalan D
,
Coleman M
,
Pearse RN
,
Y Wang L
,
Lent R
,
Christos PJ
,
Lee JW
,
Agrawal YP
,
Matthew S
et al.
. 2008.
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
.
Br J Haematol. 143(5):654-60.